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Subjects with baseline mini-mental state examination 
(MMSE) scores of mild to moderate Alzheimer’s disease 
(AD) were treated with algal docosahexaenoic acid 
(DHA, 2,000  mg/day) for 18 months in a randomized 
double-blind placebo-controlled trial to determine the 
impact on AD progression. Th e rationale for testing DHA 
was strong. It is enriched in neuronal membranes but 
depleted in AD. Multiple epidemiological studies report 
diets rich in fi sh or DHA reduce AD risk, most clearly in 
non-apolipoprotein E4 (ApoE4) carriers [1]. Preclinical 
studies with DHA have not yet modeled ApoE isoform 
pharmacogenomics, but mice transgenic for familial 
dominant AD mutations that elevate β-amyloid (Aβ) 
production are vulnerable to dietary DHA depletion. 
DHA and its metabolites pleiotropically impact Aβ pro-
duc tion, insulin/neurotrophic signaling, tau kinase 
activa tion and synaptic plasticity [1]. Although DHA had 
no impact on cognitive or functional decline based on 
intent to treat AD, in non-ApoE4 carriers, DHA supple-
mentation appeared to reduce declines in MMSE and 
Alzheimer Disease Assessment Scale-Cognitive (ADAS-
Cog). Th is commentary discusses the trial’s results and 
important questions raised, including the need for 
optimization of dose and antioxidant combinations and 
whether there should be further investigation of the 
impact of DHA on slowing cognitive decline in non-
ApoE4 carriers. Perhaps a larger issue is whether agents 
directed at amyloid or tau pathology or associated with 
reduced AD risk should be translated with an intent-to-
treat earlier disease stages rather than mild to moderate 
AD.
Th e randomized trial of DHA for AD provides evidence 
that DHA supplementation provides no general benefi t 
to AD patients, including no overall impact on Clinical 
Dementia Rating (CDR) scale, ADAS-Cog, MMSE, 
Neuropsychiatric Inventory (NPI; P = 0.11) and Activities 
of Daily Living (ADL) [2]. Th e authors argue that DHA 
may still have potential for prevention. Th us, a 
fundamental question arising out of this study is the stage 
at which we should treat. First, three smaller studies 
showed an apparent benefi t from fi sh oil treatment in 
mild cognitive impairment but not in mild to moderate 
AD subjects [3-5]. With age-associated memory 
Abstract
The results of a randomized double-blind placebo-
controlled trial with docosahexaenoic acid (DHA) 
supplementation in mild to moderate Alzheimer’s 
disease (AD) published by Quinn and colleagues 
in JAMA argues against overall effi  cacy of DHA 
in slowing progression. However, certain caveats 
in the results caution against discarding DHA 
altogether, raising questions about oxidation, dosage, 
pharmacogenomics and stage of intervention. 
One potential misconception is that what works 
for prevention will slow progression in AD subjects. 
Preclinical studies with DHA supported the rationale 
for early stage intervention; and three epidemiological 
studies indicated DHA intake was associated with 
reduced risk in non-apolipoprotein E4 (ApoE4) 
carriers. Putative drugs are initially tested for impact 
on progression because prevention approaches are 
problematic. However, should a drug be discarded for 
prevention if it fails to modify progression? Consistent 
with epidemiology, DHA signifi cantly benefi ted two 
measures of cognition in mild to moderate non-
ApoE4 carriers. Although the results of this trial were 
overall negative, failing to modify other outcomes, this 
commentary discusses important questions raised by 
them. Should future trials pursue DHA in non-ApoE4 
carriers for slowing progression? Since in vivo oxidation 
of DHA may have adverse eff ects, particularly in ApoE4 
patients, should preclinical and clinical studies be 
performed to optimize dose and mitigate oxidation 
before pursuing intervention or prevention trials with 
DHA? And fi nally, should DHA be tested now for mild 
cognitive impairment or prevention?
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impairment, one small trial [6] and the larger 485-subject 
MIDAS (Memory Improve ment with DHA Study) trial 
[7] found signifi cant cognitive benefi ts with DHA. While 
there have been two fi sh oil trials in unimpaired elderly in 
which no cognitive benefi ts were observed [8,9], subjects 
in both were cognitively normal at baseline, and the latter 
failed to show signifi cant cognitive decline in the placebo 
group. Th is study argues that fi sh oil is not a cognitive 
enhancer, but does not examine disease modifi cation in 
subjects with pathology-driven memory defi cits. Second, 
animal studies report DHA/fi sh oil act on two 
pathological endpoints that plateau by mild to moderate 
stages: Aβ accumulation [10] and loss of superior cortical 
drebrin, an excitatory synaptic marker [11] (reviewed in 
[1]). Dramatic medial and superior temporal drebrin loss 
plateaus early with mild cognitive impairment by MMSE 
26 [12], so loss has already occurred in trial subjects. 
While DHA reduced both Aβ and tau pathology in 3xTg 
AD mice [13], that intervention was early (pre-
pathology). In contrast, with late post-pathology inter-
vention in human tau transgenic mice with signi fi cant 
neuron loss, we fi nd DHA treatment is insuffi  cient to 
produce signifi cant cognitive and synaptic improve ments 
(GMC and SAF, Society for Neuroscience presen tations, 
2010). Finally, epidemiological risk factors may be 
relevant to prevention, but not necessarily to treatment. 
Animal model data with DHA support early intervention 
for primary prevention or mild cognitive impairment and 
suggest a failure to impact tangle and neuron loss driven 
defi cits at later stages.
Although the data demonstrate that DHA has no 
general benefi t for AD, a concern remains as to whether 
the key negative eff ect may be driven by the failure of 
ApoE4 subjects to respond. Since non-ApoE4 carriers 
comprise a large segment of the US (approximately 75%) 
and AD (approximately 50%) populations, whether DHA 
may slow progression in non-ApoE4 carriers is impor-
tant. Figure 3 in [2] indicates that 40% of non-ApoE4 
carriers showed signifi cant (P = 0.03) stabilization of both 
ADAS-Cog and MMSE, but not with correction for 
multiple comparisons. Th e authors point out that three 
epidemio logical studies showed reduced risk with fi sh 
consump tion only in the ApoE4 non-carriers, but add 
that pharmacogenomic interaction was not seen with 
CDR, ADL or NPI. For example, NPI showed a trend 
indepen dent of genotype, worsening less (2.93 points) in 
the DHA group than in the placebo group (5.09 points, 
P  =  0.11). Are pathogenic mechanisms impacting NPI, 
ADL, CDR and MMSE/ADAS-Cog the same? Th us, any 
pharmacogenomic potential of DHA requires clarifi  cation.
For prevention or treatment, one might expect ApoE 
genotype-DHA interactions. Because ApoE4 accelerates 
pathogenesis, age-matched ApoE4 patients may have 
more intractable AD pathology. Further, one important 
target of DHA is insulin resistance [14], but drugs target-
ing insulin resistance (insulin or peroxisome proliferator-
activated receptor (PPAR)γ agonists) appears more 
eff ective at reducing cognitive defi cits in ApoE3 carriers 
than ApoE4 carriers [15]. ApoE is a major central nervous 
system lipid transport protein with isoform-dependent 
traffi  cking likely to impact DHA compartmentalization 
in the brain. Finally, ApoE4 increases oxidative stress, 
and with six double bonds, DHA is readily oxidized.
Th is raises other critical issues that need to be 
addressed before pursuing a future trial: dose and oxida-
tion. Th e authors discuss the need to investigate potential 
combinations of DHA with antioxidants in AD patients, 
given apparent benefi ts with combinations of fi sh oil and 
lutein or lipoate in small trials and with antioxidants in 
the Souvenaid trial. Oxidation of DHA to neuroprostanes 
is associated with synaptic loss. Further oxidation 
produces a toxic end-product, 4-hydroxyhexenal, that 
contributes to neuron death and defective uptake of 
glucose by neurons and glutamate by astrocytes. Clinical 
studies demonstrate that similar dosing with marine n-3 
fatty acids (polyunsaturated fatty acids with a double 
bond at the third carbon), including DHA, can deplete 
vitamin E and increase some peripheral measures of 
oxidative damage, particularly with dosing up to 
6  months [16]. Because DHA is enriched in the brain 
where oxidative damage is already increased in AD 
patients, antioxidant supplements optimized for AD 
brain appear crucial. Even though marine n-3 fatty acids 
can deplete vitamin E, high dose vitamin E (900 IU) did 
not reduce measures of lipid peroxidation in human 
plasma [17], so vitamin E supplementation is probably 
not suffi  cient. In mice the lipophilic phenolic antioxidant 
food additive butylhydroxytoluene attenuated measures 
of lipid peroxidation in plasma after high intake of fi sh oil 
[18]. Th e preclinical studies with DHA in AD mouse 
models require encapsulation of DHA in the chow to 
minimize oxidation [10,11]. Also, using the US Food and 
Drug Administration’s equation to estimate the human 
equivalent doses, the clinical trial dose was three-fold 
higher than the effi  cacious preclinical dose in mice 
[10,11], and twice as high as in the MIDAS trial [7], 
raising questions about whether the dose may have been 
too high, potentially exacerbating oxidative damage.
Possible cognitive benefi ts in patient subgroups 
(pharma co genomic or otherwise) would be strengthened 
by evidence of a biomarker response, arguing for the 
need to validate neuroimaging, cerebrospinal fl uid or 
plasma biomarker responses in preclinical studies going 
forward. MRI was performed in a small subset of 
subjects, showing that volumentrics of the left hippo-
campus in the DHA group showed trends to be smaller 
than in the placebo group (P = 0.17), which may indicate 
brain shrinkage. In the AN1792 active Aβ vaccination, 
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MRI shrinkage was attributed to plaque clearance. Since 
drugs may only work in a subset of patients, it would be 
helpful in large studies where neuroimaging or 
cerebrospinal fl uid biomarker analysis are less feasible to 
identify likely responders with plasma biomarkers. A 
diffi  cult task at hand is to design future DHA or other 
trials with earlier intervention to include validated 
surrogate and/or diagnostic biomarkers that have shown 
DHA responses in animal models. For tracking adverse 
eff ects of DHA, it is important to measure blood vitamin 
E depletion and lipid peroxides (thiobarbituric acid 
reactive substances, malondialdehyde, or the specifi c 
byproduct of DHA oxidation, 4-hydroxyhexenal). 
Biomarker validation could track mechanisms and lower 
trial costs and facilitate choice of effi  cacious doses before 
proceeding to longer term, more costly trials to evaluate 
conversion to AD.
Conclusion
Th e study by Quinn and colleagues provides additional 
rationale to test DHA for prevention, with focus on non-
ApoE4 carriers, but problems with DHA dosing and 
oxidation need to be addressed (particularly if an 
antioxidant could correct a failed ApoE4 response to 
DHA). Additional preclinical studies of stage-dependent 
effi  cacy and ApoE4-DHA interaction may help to clarify 
whether ApoE genotype aff ects outcomes and how this 
can be mitigated, possibly with antioxidants or non-
steroidal anti-infl ammatory drugs (NSAIDs). Beyond 
pharmacogenomic roadblocks emerging with DHA and 
other interventions, all of the epidemiology and most of 
the animal model data that have been generated are most 
relevant to early stage interventions, but have been 
translated in clinical trials in mild to moderate AD, 
potentially resulting in an intent-to-treat the wrong 
group. Th e pre-clinical conclusions may not be wrong, 
but simply still lost in this translation.
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